Table of Contents

Takeaways

    • Wegovy HD is semaglutide 7.2 mg once weekly. It is the highest approved Wegovy injection strength listed in current FDA labeling.
    • Higher-dose Wegovy worked better in clinical trials, with 7.2 mg leading to greater average weight loss than 2.4 mg.
    • You should not start Wegovy at 7.2 mg. Wegovy injection starts at 0.25 mg weekly and is increased gradually.
    • Side effects are still mostly digestive, including nausea, vomiting, constipation, and abdominal pain. Dysesthesia, which can feel like burning, tingling, sensitive skin, or skin pain, was much more common with the 7.2 mg dose.
    • Cost and coverage vary. NovoCare lists promotional self-pay pricing and states that after certain starter-dose fills, Wegovy HD is $399 per month under that program, with eligibility restrictions. But the retail price may be over $1,349 per month.

For years, the highest Wegovy injection dose for weight management was 2.4 mg once weekly. Now, Wegovy 7.2 mg gives some adults a higher-dose option when they need more weight loss and can tolerate treatment.

However, not everyone can move up to this dose. This guide explains what the Wegovy 7.2 mg dose is, how it compares with Wegovy 2.4 mg, what side effects to watch for, and how much it may cost.

Quick answer

Wegovy 7.2 mg, also called Wegovy HD, is a once-weekly higher-dose semaglutide injection approved by the FDA in March 2026 for weight loss in certain adults with obesity or overweight with at least one weight-related condition. It’s an additional option that may offer greater weight loss for some adults.

In trials, adults with obesity lost an average of 18.7% of body weight with Wegovy 7.2 mg, compared with 15.6% with Wegovy 2.4 mg and 3.9% with placebo at 72 weeks. In a separate study of adults with type 2 diabetes and obesity, the average loss was 13.2% with Wegovy 7.2 mg, compared with 10.4% with 2.4 mg and 3.9% with placebo.

Wegovy 7.2 mg is not a starting dose. The Wegovy injection schedule still starts at 0.25 mg once weekly for 4 weeks, then increases gradually to reduce gastrointestinal side effects. The recommended adult maintenance dose for weight reduction is still 2.4 mg once weekly, and may only be increased to 7.2 mg once weekly when clinically indicated.

What is Wegovy HD 7.2 mg?

Wegovy HD 7.2 mg is a higher-dose version of Wegovy injection. It contains semaglutide, the same active ingredient in standard Wegovy, but at a higher once-weekly maintenance dose.

Is Wegovy 7.2 mg FDA-approved?

Yes. The FDA approved Wegovy HD 7.2 mg in March 2026. The FDA press announcement states that the new higher dose was approved for adults with obesity, or adults with overweight and at least one weight-related condition.

The current FDA label lists Wegovy injection strengths that include:

    • 0.25 mg
    • 0.5 mg
    • 1 mg
    • 1.7 mg
    • 2.4 mg
    • Wegovy HD 7.2 mg

It also lists Wegovy tablets in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths.

Do higher doses of Wegovy work better?

Yes, higher-dose Wegovy 7.2 mg worked better on average than Wegovy 2.4 mg in clinical trials.

In the STEP UP trial, average weight loss of adults with obesity but without diabetes was 18.7% with 7.2 mg, compared with 15.6% with 2.4 mg and 3.9% with placebo. For someone weighing 250 pounds, that difference would be almost 8 additional pounds on average, though individual results can vary.

People taking 7.2 mg were also more likely to lose 20% or more and 25% or more of their starting body weight. The 7.2 mg dose also reduced waist circumference more than placebo, with an estimated additional reduction of 11.7 cm after 72 weeks. 

In the STEP UP T2D trial, adults with obesity and type 2 diabetes who took Wegovy 7.2 mg once weekly lost an average of 13.2% of their body weight after 72 weeks, compared with 10.4% with 2.4 mg and 3.9% with placebo.

Clinical trial averages are not guarantees. Some people lose much more than the average, and some lose less. Your results depend on several factors, such as dose tolerance, adherence, lifestyle, other medications, hormones, starting weight, and other medical conditions.

Who may be a candidate for Wegovy 7.2 mg?

In an interview with ABC News, Dr. Alok Patel explained that the new dose is intended for people who tried earlier, lower doses (2.4 mg) but did not get the results they wanted. He also emphasized that this should be done under the guidance of a healthcare professional.

You might want to discuss Wegovy HD with your clinician if:

    • You’re already on Wegovy 2.4 mg and tolerating it
    • Have not reached a reasonable weight-loss goal on 2.4 mg
    • Still meet medical criteria for chronic weight management
    • Can maintain enough hydration, protein, and calorie intake
    • Do not have side effects that make dose escalation unsafe

The 7.2 mg dose may not be appropriate if you have experienced severe side effects, such as uncontrolled vomiting or severe dehydration, while on lower doses of Wegovy.

What is the difference between 2.4 mg and 7.2 mg semaglutide?

The main difference is dose strength. Wegovy 7.2 mg delivers three times the amount of semaglutide as Wegovy 2.4 mg in a once-weekly injection. In studies, the 7.2 mg dose produced more average weight loss, but also had higher rates of some side effects.

Results of Wegovy 7.2 mg vs Wegovy 2.4 mg

Feature

Wegovy 2.4 mg

Wegovy HD 7.2 mg

Active ingredient

Semaglutide

Semaglutide

Drug class

GLP-1 receptor agonist

GLP-1 receptor agonist

Frequency

Once weekly

Once weekly

STEP UP trial (adults with obesity but without diabetes)
Average weight loss

15.6%

18.7%

% of patients losing at least 5% body weight

86.6%

88.7%

% of patients losing at least 10% body weight

72%

79.8%

% of patients losing at least 15% body weight

52.3%

63.8%

% of patients losing at least 20% body weight

32.3%

45.5%

STEP UP T2D trial (adults with obesity and diabetes)
Average weight loss

10.4%

13.2%

% of patients losing at least 5% body weight

74%

83.7%

% of patients losing at least 10% body weight

49.5%

60.7%

% of patients losing at least 15% body weight

27%

39.8%

% of patients losing at least 20% body weight

13.5%

20.6%

Sources: FDA Wegovy prescribing information.

Why does Wegovy jump from 2.4 mg to 7.2 mg?

One likely reason is that smaller increases like 3 mg or 4.5 mg may not have shown a meaningful difference from 2.4 mg to support a distinct higher-dose option.

In one Reddit discussion, a few users said they were moving to 7.2 mg because 2.4 mg had stopped working well for them. One person said they had lost about 40 pounds, but their weight had not moved for six months on 2.4 mg. After the second week on 7.2 mg, they reported losing 3 pounds.

Some Reddit users also discussed more personalized dosing approaches, such as using two 2.4 mg injections before moving up to 7.2 mg, so the increase would feel more gradual.

The main takeaway is that people are mostly considering 7.2 mg after a weight-loss plateau.

Can you start Wegovy at 7.2 mg?

No. Wegovy 7.2 mg is not a starting dose.

The standard Wegovy injection escalation schedule is:

Weeks Dose
1 to 4 0.25 mg once weekly
5 to 8 0.5 mg once weekly
9 to 12 1 mg once weekly
13 to 16 1.7 mg once weekly
17 and onward Maintenance dose based on indication and tolerability (1.7 mg or 2.4 mg)

It’s also recommended that if you do not tolerate a dose during escalation, your doctor may consider delaying dose escalation for 4 weeks.

What is the strongest strength of Wegovy?

Currently, the strongest Wegovy injection strength is 7.2 mg (Wegovy HD).

There is also a Wegovy tablet approved in strengths up to 25 mg once daily, but oral semaglutide dosing is not directly comparable to injection dosing. Oral semaglutide has much lower absorption, and the FDA label notes that the absolute bioavailability of semaglutide after oral tablet administration is about 1% to 2%.

Is Wegovy stronger than Ozempic?

Wegovy is generally stronger than Ozempic because it is specifically formulated with higher semaglutide doses. Wegovy injection now includes a 7.2 mg high-dose option, while Ozempic’s highest dose is only 2 mg.

Is Wegovy 7.2 as good as Mounjaro or Zepbound?

Wegovy 7.2 mg appears to narrow the weight-loss gap with Zepbound and Mounjaro, but it has not been directly compared with tirzepatide in a head-to-head trial.

In separate studies, Wegovy 7.2 mg produced about 18.7% average weight loss over 72 weeks, while the highest tirzepatide dose used for Zepbound produced about 20.9% to 22.5% average weight loss.

Zepbound and Mounjaro still tend to show slightly better weight-loss results in clinical trials.

What is Wegovy 7.2 equivalent to Mounjaro?

Wegovy 7.2 mg has no equivalent Mounjaro dose. Mounjaro contains tirzepatide, not semaglutide. Your clinician may switch you from Wegovy to Mounjaro, but the decision is based on medical history, response, side effects, and dosing tolerance. It’s not a simple mg-to-mg conversion.

What are the side effects of Wegovy 7.2 mg?

The most common side effects of Wegovy 7.2 mg are still mostly gastrointestinal, but dysesthesia was notably more common at the higher dose. Dysesthesia can feel like burning, tingling, skin pain, sensitive skin, or abnormal skin sensations.

Side effects reported in Wegovy 7.2 mg trials

Side effect

Placebo Wegovy 2.4 mg

Wegovy 7.2 mg

Nausea

13%

35%

39%

Vomiting

6%

16%

22%

Dysesthesia

0%

6%

22%

Constipation

8%

19%

20%

Abdominal pain

7%

9%

12%

Fatigue

5%

9%

11%

Headache

7%

8%

9%

Dizziness

1%

5%

6%

Hair loss

1%

3%

6%

Flatulence

2%

2%

4%

Source: FDA Wegovy prescribing information.

Personal experiences with Wegovy 7.2 mg appear to vary widely. On Reddit, some users reported little to no major side effects and said they started losing weight again after stalling on 2.4 mg.

Others reported intense nausea, vomiting, diarrhea, dizziness, weakness, and unusual skin sensations after the first dose.

How much will Wegovy 7.2 mg cost?

Wegovy HD 4-pen package costs $1,349.02 before insurance, coupons, or other discounts. NovoCare Pharmacy offers it for $399 per month, but this comes with certain eligibility requirements.

Is Wegovy 7.2 covered by insurance?

Yes, Wegovy 7.2 mg may be covered by some insurance plans. It is also included in the Medicare GLP-1 Bridge, which allows eligible Medicare Part D beneficiaries to access covered GLP-1 medications for weight management for a $50 monthly copay.

Commercially insured patients may also pay as little as $25 through NovoCare Pharmacy.

Many plans require:

    • A diagnosis of obesity or overweight with a weight-related condition
    • BMI documentation
    • Prior authorization
    • Evidence of lifestyle intervention
    • Follow-up weight measurements
    • Continued benefit to renew coverage
    • Documentation that the dose is medically needed

For the most accurate and up-to-date coverage information, contact your insurance plan directly and ask whether Wegovy 7.2 mg is covered, what prior authorization requirements apply, and what your estimated out-of-pocket cost would be.

Frequently Asked Questions

No. Wegovy does not have a 7.5 mg injection dose. The high-dose Wegovy injection strength is 7.2 mg. The 7.5 mg dose is more commonly associated with tirzepatide dosing.
For Wegovy injection, the highest dose is 7.2 mg once weekly. For tablets, the highest dose is 25 mg once daily.
It may be more expensive depending on your insurance or pharmacy pricing. NovoCare’s self-pay program lists $399 per month for Wegovy HD after specific starter-dose promotional pricing, compared with $199 per month for certain lower injection doses under that program.
Some people may lose 20 pounds in 2 months, especially if they start at a higher body weight, but it is not guaranteed and may be too fast for some patients. Wegovy dosing starts low and increases gradually, so early weight loss varies. Focus on safe progress, hydration, protein, and follow-up care.
People stop Wegovy because of side effects, cost, insurance denials, supply issues, pregnancy planning, surgery, or personal preference. In 7.2 mg trials, 5% of patients on 7.2 mg stopped permanently because of adverse reactions.
Yes, some people keep some weight off, but weight regain is common. In the STEP 1 extension, participants regained about two-thirds of their previous weight loss one year after stopping semaglutide 2.4 mg and lifestyle intervention.

Bottom line

Wegovy HD 7.2 mg is a new higher-dose option used when Wegovy 2.4 mg is not enough. In trials, it helped people lose more weight than lower Wegovy doses, and more patients reached larger weight-loss milestones.

But higher-dose Wegovy is not for everyone. A higher dose may not be needed if you are still losing weight steadily, cannot eat enough protein, or have significant side effects. It may be more reasonable if your weight has plateaued despite adherence and you tolerate 2.4 mg well.

Call your insurer before filling the prescription. Ask whether Wegovy HD is covered, whether prior authorization is required, and whether the pharmacy can order it.

  • Lingvay, I., Bergenheim, S. J., Buse, J. B., Freitas, P., Garvey, W. T., Harder-Lauridsen, N. M., Rosenstock, J., Sahu, K., & Wharton, S. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology, 13(11), 935–948. https://doi.org/10.1016/s2213-8587(25)00225-6
  • Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology, 13(11), 949–963. https://doi.org/10.1016/s2213-8587(25)00226-8
  • Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
  • Wegovy. (n.d.). https://www.novopricing.com/wegovy.html
  • Wegovy® (semaglutide) Online Pharmacy | NovoCare®. (n.d.). https://www.novocare.com/pharmacy/wegovy.html